Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia
Recruiting
Observational Study
Acute Myeloid Leukemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 80 (estimated)
- Sponsor
- Ciceri Fabio · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Any gender,
* Adults (\>18 years old),
* New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)
* Capable of comprehend the study and the consent form,
* Willing to sign the informed consent for the study.
For the retrospective population we will select:
biologic…
Contacts